GlassScriptPhysician profile
Sam J Nassar
NPI 1972624229
$2,862.21
in general payments reported to CMS, 2019-2025
33 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $61.38 · 2021: $306 · 2022: $493 · 2023: $733 · 2024: $377 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $666.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $224.49 | 2019-2024 | |
| Medtronic, INC. | $212.07 | 2021-2025 | Symplicity G3, Corevalve Evolut R |
| Biotronik INC. | $181.56 | 2019-2022 | |
| Abbott Laboratories | $178.11 | 2019-2025 | Allure Quadra, Na, Accent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.36 | 2019-2024 | Jardiance |
| Inspire Medical Systems, INC. | $121.52 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $119.18 | 2022-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $107.82 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $89.76 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $71.13 | 2019-2022 | |
| Novo Nordisk INC | $64.73 | 2022-2025 | Wegovy |
| Heartflow, INC. | $63.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $62.27 | 2019-2021 | |
| Atricure, INC. | $54.47 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $51.00 | 2022-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.76 | 2023-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $44.27 | 2025 | Onpattro |
| Ardelyx, INC. | $40.54 | 2025 | Ibsrela |
| Boston Scientific Corporation | $34.86 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $33.97 | 2021-2023 | Arcalyst |
| Edwards Lifesciences Corporation | $29.85 | 2023 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $28.62 | 2021 | |
| Braemar Manufacturing, LLC | $28.44 | 2019 | |
| Cardiovascular Systems INC. | $26.33 | 2021 | |
| Tactile Systems Technology INC | $25.22 | 2022 | |
| Redhill Biopharma INC. | $21.47 | 2023 | Talicia |
| Kiniksa Pharmaceuticals International, Plc | $19.31 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $18.26 | 2024 | |
| Analog Devices INC. | $15.10 | 2024 | Sensinel Cpm Wearable |
| Bayer Healthcare Pharmaceuticals INC. | $13.85 | 2022 | |
| Kestra Medical Technology Services, INC. | $13.70 | 2025 | Assure Wcd |
| Cvrx, INC. | $12.15 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Nassar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.